BusinessImmuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US MarketsBy Nasdaq OMXApr 23, 2018, 1:30 PM UTC
BusinessTravelan® Revenue Grows Significantly in US and AustraliaBy Nasdaq OMXFeb 16, 2018, 2:30 PM UTC
BusinessUS Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and ShigellaBy Nasdaq OMXJan 29, 2018, 2:20 PM UTC
